Green Biologics Ltd., based near Oxford, UK, has closed a £15.4 million (~ $25 million) Series B round led by Sofinnova Partners with strategic participation by Swire Pacific Limited. Follow on investments were also made by funds advised by Capricorn Venture Partners and Oxford Capital Partners and by Morningside Ventures and ConvergInce Holdings LLC.

The investment round will allow the company to execute its plans to bring on stream GBL’s first commercial production facility in the U.S. in 2016.